Mold, ceiling holes cited in CP Pharma warning

Mold in a class 100 production room and holes in a ceiling at a CP Pharmaceuticals plant in Wrexham, U.K., are part of a list of violations identified by FDA inspectors in Warning Letter 320-11-002. The letter follows a July inspection. Because CP took more than 15 days to reply to the Form 483 report issued after the inspection, the regulator doesn't acknowledge them in the warning.

The mold and the holes are some of the building-related inspection details the FDA documents. Inspectors note the holes in the ceiling of a freeze dryer room and say they saw outside light entering in the vicinity of the ventilation system. The letter says the room is subject to regular maintenance, yet the holes remain despite an incident report from late last year that describes them. Another item from the incident report: bubbling vinyl and disintegration of the wall beneath it.

Inspectors found more mold in a class 10,000 area, almost a year after it was first seen there. The warning cites CP for lack of a schedule for cleaning with a spore killer.

- here's the warning letter


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.